title: [Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients].
abstract: We studied the pharmacokinetics of 5-FU after S-1 oral administration at the usual dose (80 mg/m2) for adjuvant chemotherapy in 13 advanced gastric cancer patients (Stage II, III), and at a decreased dose (60 mg/m2) for adjuvant or combined chemotherapy in 13 advanced gastric cancer patients. Pharmacokinetic parameters of 5-FU in the serum were as follows: Cmax, 159 .9 2+/-45.2 ng/mL, Tmax, 2.17+/-0.58 h;T1/2, 3.13+/-2.88 h; and AUC(0-8), 768.0+/-260.8 ng h/mL in the patients with the usual dose, and Cmax, 117.3+/-55.1 ng/mL; Tmax, 2.62+/-0.9 6 h; T1/2, 3.09+/-1.9 5 h and AUC(0-8), 565.9+/-216.8 ng h/mL in the patients with the decreased dose. No difference in AUC was observed between operative methods. Adverse events of more than grade 3 were recognized in 7 patients, and AUC of 6 patients were more than 800 ng h/mL. The plasma concentration of 5-FU was quite different between patients. The difference of Cmax and AUC was 3-4 times. It was concluded that we must pay attention to individual differences in the plasma concentration of 5-FU in postoperative gastric cancer patients when S-1 would be administered.
authors.affiliation: Department of Surgery, Division of Gastroenterology, Kawasaki Medical School.
authors.forename: Hideo
authors.initials: H
authors.lastname: Matsumoto
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Hirai
authors.forename: Yohko
authors.initials: Y
authors.lastname: Hirabayashi
authors.forename: Haruaki
authors.initials: H
authors.lastname: Murakami
authors.forename: Masaharu
authors.initials: M
authors.lastname: Higashida
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Kawabe
authors.forename: Michihisa
authors.initials: M
authors.lastname: Fuchimoto
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Fujikura
authors.forename: Shinji
authors.initials: S
authors.lastname: Hato
authors.forename: Atsushi
authors.initials: A
authors.lastname: Urakami
authors.forename: Kazuki
authors.initials: K
authors.lastname: Yamashita
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Tsunoda
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000097:blood; D017024:Chemotherapy, Adjuvant; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000493:pharmacokinetics*; D005743:Gastrectomy / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage*; D013274:Stomach Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D005472:Fluorouracil